A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions

Covid19

Interventions

DRUG

RTB101

Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks

DRUG

Placebo

Oral matching placebo once daily for 2 weeks

Trial Locations (2)

University of Connecticut, UConn Center on Aging, Farmington

Hebrew Senior Life, Marcus Institute for Aging Research, Roslindale

All Listed Sponsors

collaborator

National Institute on Aging (NIA)

NIH

lead

Restorbio Inc.

INDUSTRY

NCT04584710 - A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults | Biotech Hunter | Biotech Hunter